Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug

We report a first-in-patient study of vamorolone, a first-in-class dissociative steroidal anti-inflammatory drug, in Duchenne muscular dystrophy. This 2-week, open-label Phase IIa multiple ascending dose study (0.25, 0.75, 2.0, and 6.0 mg/kg/day) enrolled 48 boys with Duchenne muscular dystrophy (4...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacol Res
Main Authors: Conklin, Laurie S., Damsker, Jesse M., Hoffman, Eric P., Jusko, William J., Mavroudis, Panteleimon D., Schwartz, Benjamin D., Mengle-Gaw, Laurel J., Smith, Edward C., Mah, Jean K., Guglieri, Michela, Nevo, Yoram, Kuntz, Nancy, McDonald, Craig M., Tulinius, Mar, Ryan, Monique M., Webster, Richard, Castro, Diana, Finkel, Richard S., Smith, Andrea L., Morgenroth, Lauren P., Arrieta, Adrienne, Shimony, Maya, Jaros, Mark, Shale, Phil, McCall, John M., Hathout, Yetrib, Nagaraju, Kanneboyina, van den Anker, John, Ward, Leanne M., Ahmet, Alexandra, Cornish, Michaelyn R., Clemens, Paula R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6218284/
https://ncbi.nlm.nih.gov/pubmed/30219580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.phrs.2018.09.007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados